PROGNYX

Home/The Watchtower/Summit's ivonescimab draws an FDA complete response lette…

Editorial illustration for the Prognyx briefing on ivonescimab, PD-1 x VEGF bispecific antibody

Briefing · From the Watchtower

Summit's ivonescimab draws an FDA complete response letter in post-EGFR-TKI NSCLC

By · Founder, Prognyx ● Sourced to primary records Oncology
In brief: On 15 November 2026, Summit Therapeutics disclosed that the FDA issued a complete response letter for ivonescimab plus platinum chemotherapy in locally advanced or metastatic NSCLC after prior EGFR TKI therapy, finding the HARMONi trial's progression-free survival benefit insufficient to establish effectiveness without a statistically significant overall survival improvement.

On 15 November 2026, Summit Therapeutics disclosed in a securities filing that the FDA had issued a complete response letter for ivonescimab combined with platinum chemotherapy in locally advanced or metastatic non-small cell lung cancer in patients previously treated with an EGFR tyrosine kinase inhibitor [1]. The agency said the application cannot be approved as submitted: it determined that substantial evidence of effectiveness was not established without a statistically significant overall survival improvement, and that the progression-free survival benefit alone does not support a positive benefit-risk profile [1].

This was telegraphed. In its 4 November 2026 filing, Summit noted the FDA had previously said a statistically significant OS benefit was necessary to support approval in this setting, against a PDUFA target action date of 14 November 2026 [3]. Endpoints News reports the rejection was a decision analysts largely expected, and one that should not dim the drug's prospects [2].

Why it matters

Ivonescimab is a PD-1 and VEGF bispecific antibody [4], and its HARMONi program is the asset's path to a US launch. The CRL turns on a specific evidentiary bar: the FDA wanted mature, statistically significant OS rather than a PFS win paired with an OS trend. In a post-hoc analysis with longer follow-up, Summit reported a consistent OS benefit with a hazard ratio of 0.76 in the full population, the Asian patients, and the western patients [1]. A post-hoc 0.76 is directionally supportive, but the agency's message is that post-hoc OS does not clear the threshold a registrational filing needs here. For any developer building a PD-(L)1/VEGF bispecific toward a US filing, the read is that PFS-led packages face an OS-maturity gate.

Safety was not the obstacle. Discontinuations for treatment-related adverse events ran at 7.3% (16 patients) on ivonescimab versus 5.0% (11) on placebo, and treatment-related deaths were lower in the ivonescimab arm, 1.8% (4) against 2.3% (5) in the chemotherapy-alone arm [1].

Who is exposed

Summit carries the direct hit: its near-term US regulatory catalyst is now a resubmission of unknown timing. Those bets sit outside the CRL's scope.

What to watch next

The HARMONi pivotal trial is active but no longer recruiting [5], so the near-term question is data maturity, not new enrollment.

The now-what

Three options are on the table for operators tracking this. First, if you run a PD-(L)1/VEGF bispecific, treat OS maturity as a gating assumption for US registration and resource your trials accordingly. Second, partners and acquirers can read AstraZeneca's structure, equity plus tumour-agnostic ADC combinations, as a template for valuing ivonescimab independent of this one label. Third, for anyone sequencing post-TKI EGFR NSCLC therapy, the US standard of care does not change on this news.

What Prognyx could not verify

No source in this dossier states whether or when Summit will resubmit the BLA, nor the specific OS data maturity the FDA will require. Summit's stock reaction to the disclosure is not in the record.

Verdict: the threat is contained to Summit's US timeline; the window to act is the resubmission schedule, currently undisclosed.

Questions this briefing answers

Why did the FDA reject ivonescimab's lung cancer application?

The FDA determined the BLA cannot be approved as submitted because substantial evidence of effectiveness was not established without a statistically significant overall survival improvement; the progression-free survival benefit alone did not support a positive benefit-risk profile [1].

Does the complete response letter affect AstraZeneca's investment in Summit?

AstraZeneca's $2 billion equity investment, disclosed 29 September 2026, and its ADC combination collaborations, including Datroway with Daiichi Sankyo, were tied to ivonescimab's broader potential across tumour types and are not specific to the rejected NSCLC indication [4][6].

Want this on your pipeline?
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.

Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use.